Format

Send to

Choose Destination
Fam Cancer. 2018 Jul;17(3):431-434. doi: 10.1007/s10689-017-0048-0.

Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.

Author information

1
Department of Clinical Cancer Genetics, MD Anderson Cancer Center, 1155 Pressler Street CPB5.3535, Houston, TX, 77030, USA. dsaporito@mdanderson.org.
2
Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
3
Division of Human Genetics, Department of Internal Medicine and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
4
Division of Endocrinology, Diabetes and Metabolism, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
5
Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
6
Department of Cancer Biology and Genetics and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
7
Senior Medical Science Liaison, Guardant Health, Redwood City, CA, USA.

Abstract

Familial non-medullary thyroid cancer (FNMTC) is clinically defined as two or more first-degree relatives with NMTC and appears to follow an autosomal dominant inheritance pattern. Approximately 5-7% of NMTC is hereditary and affects multiple generations with a young age of onset. The primary aim of this study was to determine the age-specific penetrance of NMTC in individuals from a large family with FNMTC with a previously identified private mutation at 4q32, with a secondary aim to determine the penetrance for benign thyroid disease in this family. We present a large family with NMTC in which we had previously described a culpable mutation. Participants provided their personal medical history and family history. The germline 4q32 A > C mutation was detected in 34 of 68 tested individuals. Age-specific penetrance of thyroid cancer and benign thyroid disease was determined using the inverted Kaplan-Meier method of segregation analysis. Individuals who tested positive for the 4q32 mutation have a 68.9% (95% CI 46.5-88.7) risk of developing thyroid cancer by age 70 and a 65.3% (95% CI 46.0-83.8) risk of developing benign thyroid disease by age 70. The 4q32 A > C mutation significantly increases the risk to develop thyroid cancer but not benign thyroid disease in members of this family. The female:male sex ratio of 1.33 that we observed in affected mutation carriers differs greatly from the ratio of approximately 3:1 observed in PTC, supporting a central role of the mutation. Early thyroid surveillance with annual ultrasound is recommended to individuals testing positive for this private familial mutation.

KEYWORDS:

Anaplastic thyroid cancer; Benign thyroid disease; Familial non-medullary thyroid cancer; Papillary thyroid cancer; Penetrance; Risk

PMID:
29027612
PMCID:
PMC5897192
DOI:
10.1007/s10689-017-0048-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center